The Experts below are selected from a list of 288 Experts worldwide ranked by ideXlab platform

Lennart Minthon - One of the best experts on this subject based on the ideXlab platform.

  • computerized Cognition Assessment during acetylcholinesterase inhibitor treatment in alzheimer s disease
    Acta Neurologica Scandinavica, 2010
    Co-Authors: Keith Wesnes, Chris Edgar, N. Andreasen, Peter Annas, Hans Basun, Lars Lannfelt, Henrik Zetterberg, Kaj Blennow, Lennart Minthon
    Abstract:

    Objectives - Alzheimer's disease Assessment scale-cognitive subscale (ADAS-Cog) has become a standard clinical trials outcome for Cognition, but has been recognized as deficient in areas including coverage of cognitive domains, sensitivity and standardization. Computerized test batteries may address some of these issues. The cognitive drug research computerized Assessment (CDR) system is validated in Alzheimer's disease (AD). This study was designed to further evaluate validity in relation to ADAS-Cog, mini mental state examination (MMSE) and cerebrospinal fluid (CSF) biomarkers and psychometric properties, in a population of Alzheimer's patients on stable anticholinesterase treatment. Materials and methods - Patients completed Cognition Assessments, CSF and blood sampling at baseline and 6 months later. Data for 65 patients were evaluated. Results - The CDR system demonstrated good psychometric properties in this population. Measures of psychomotor speed showed possible sensitivity to decline over 6 months. Conclusions - There are a number of methodological problems with current Cognition Assessment methodology for clinical trials. Computerized measures and in particular millisecond reaction time measures, may address many of these issues.

  • Computerized Cognition Assessment during acetylcholinesterase inhibitor treatment in Alzheimer’s disease
    Acta Neurologica Scandinavica, 2009
    Co-Authors: Keith Wesnes, Chris Edgar, N. Andreasen, Peter Annas, Hans Basun, Lars Lannfelt, Henrik Zetterberg, Kaj Blennow, Lennart Minthon
    Abstract:

    Objectives - Alzheimer's disease Assessment scale-cognitive subscale (ADAS-Cog) has become a standard clinical trials outcome for Cognition, but has been recognized as deficient in areas including coverage of cognitive domains, sensitivity and standardization. Computerized test batteries may address some of these issues. The cognitive drug research computerized Assessment (CDR) system is validated in Alzheimer's disease (AD). This study was designed to further evaluate validity in relation to ADAS-Cog, mini mental state examination (MMSE) and cerebrospinal fluid (CSF) biomarkers and psychometric properties, in a population of Alzheimer's patients on stable anticholinesterase treatment. Materials and methods - Patients completed Cognition Assessments, CSF and blood sampling at baseline and 6 months later. Data for 65 patients were evaluated. Results - The CDR system demonstrated good psychometric properties in this population. Measures of psychomotor speed showed possible sensitivity to decline over 6 months. Conclusions - There are a number of methodological problems with current Cognition Assessment methodology for clinical trials. Computerized measures and in particular millisecond reaction time measures, may address many of these issues.

Keith Wesnes - One of the best experts on this subject based on the ideXlab platform.

  • Cognition Assessment in paediatric clinical trials
    Drug Discovery Today, 2020
    Co-Authors: Chris Edgar, Keith Wesnes
    Abstract:

    As in adults and the elderly, a number of paediatric conditions have a recognised cognitive dysfunction. Studies also demonstrate adverse cognitive effects associated with medicinal products used in paediatric populations. Demonstrating efficacy in treating cognitive dysfunction, or safety and tolerability in minimising adverse cognitive effects is as relevant to paediatric clinical trials as it is to adult populations. Indeed, cognitive Assessments may be even more vital in paediatric populations, due to the additional possibility of adverse effects on cognitive development. This requirement to evaluate Cognition in children and adolescents, and new legislation for paediatric clinical trials, has created an increased demand for suitable Assessment methods.

  • computerized Cognition Assessment during acetylcholinesterase inhibitor treatment in alzheimer s disease
    Acta Neurologica Scandinavica, 2010
    Co-Authors: Keith Wesnes, Chris Edgar, N. Andreasen, Peter Annas, Hans Basun, Lars Lannfelt, Henrik Zetterberg, Kaj Blennow, Lennart Minthon
    Abstract:

    Objectives - Alzheimer's disease Assessment scale-cognitive subscale (ADAS-Cog) has become a standard clinical trials outcome for Cognition, but has been recognized as deficient in areas including coverage of cognitive domains, sensitivity and standardization. Computerized test batteries may address some of these issues. The cognitive drug research computerized Assessment (CDR) system is validated in Alzheimer's disease (AD). This study was designed to further evaluate validity in relation to ADAS-Cog, mini mental state examination (MMSE) and cerebrospinal fluid (CSF) biomarkers and psychometric properties, in a population of Alzheimer's patients on stable anticholinesterase treatment. Materials and methods - Patients completed Cognition Assessments, CSF and blood sampling at baseline and 6 months later. Data for 65 patients were evaluated. Results - The CDR system demonstrated good psychometric properties in this population. Measures of psychomotor speed showed possible sensitivity to decline over 6 months. Conclusions - There are a number of methodological problems with current Cognition Assessment methodology for clinical trials. Computerized measures and in particular millisecond reaction time measures, may address many of these issues.

  • Computerized Cognition Assessment during acetylcholinesterase inhibitor treatment in Alzheimer’s disease
    Acta Neurologica Scandinavica, 2009
    Co-Authors: Keith Wesnes, Chris Edgar, N. Andreasen, Peter Annas, Hans Basun, Lars Lannfelt, Henrik Zetterberg, Kaj Blennow, Lennart Minthon
    Abstract:

    Objectives - Alzheimer's disease Assessment scale-cognitive subscale (ADAS-Cog) has become a standard clinical trials outcome for Cognition, but has been recognized as deficient in areas including coverage of cognitive domains, sensitivity and standardization. Computerized test batteries may address some of these issues. The cognitive drug research computerized Assessment (CDR) system is validated in Alzheimer's disease (AD). This study was designed to further evaluate validity in relation to ADAS-Cog, mini mental state examination (MMSE) and cerebrospinal fluid (CSF) biomarkers and psychometric properties, in a population of Alzheimer's patients on stable anticholinesterase treatment. Materials and methods - Patients completed Cognition Assessments, CSF and blood sampling at baseline and 6 months later. Data for 65 patients were evaluated. Results - The CDR system demonstrated good psychometric properties in this population. Measures of psychomotor speed showed possible sensitivity to decline over 6 months. Conclusions - There are a number of methodological problems with current Cognition Assessment methodology for clinical trials. Computerized measures and in particular millisecond reaction time measures, may address many of these issues.

Kathleen Wallnerallen - One of the best experts on this subject based on the ideXlab platform.

  • Cognition Assessment using the nih toolbox
    Neurology, 2013
    Co-Authors: Sandra Weintraub, Sureyya Dikmen, Robert K Heaton, David S Tulsky, Philip David Zelazo, Patricia J Bauer, Noelle E Carlozzi, Jerry Slotkin, David L Blitz, Kathleen Wallnerallen
    Abstract:

    Cognition is 1 of 4 domains measured by the NIH Toolbox for the Assessment of Neurological and Behavioral Function (NIH-TB), and complements modules testing motor function, sensation, and emotion. On the basis of expert panels, the Cognition subdomains identified as most important for health, success in school and work, and independence in daily functioning were Executive Function, Episodic Memory, Language, Processing Speed, Working Memory, and Attention. Seven measures were designed to tap constructs within these subdomains. The instruments were validated in English, in a sample of 476 participants ranging in age from 3 to 85 years, with representation from both sexes, 3 racial/ethnic categories, and 3 levels of education. This report describes the development of the Cognition Battery and presents results on test-retest reliability, age effects on performance, and convergent and discriminant construct validity. The NIH-TB Cognition Battery is intended to serve as a brief, convenient set of measures to supplement other outcome measures in epidemiologic and longitudinal research and clinical trials. With a computerized format and national standardization, this battery will provide a “common currency” among researchers for comparisons across a wide range of studies and populations.

D. Trček - One of the best experts on this subject based on the ideXlab platform.

  • Reasoning Web - Trust management methodologies for the web
    Reasoning Web. Semantic Technologies for the Web of Data, 2011
    Co-Authors: D. Trček
    Abstract:

    Trust and its support with appropriate trust management methodologies and technologies is becoming one crucial element for wider acceptance of web services. In the computing society trust and related issues were addressed already in the nineties of the former century, but the approaches from that period were about security, more precisely security services and security mechanisms. These approaches were followed by more advanced ones, where the first branch was based on Bayesian statistics, the second branch was based on Dempster-Shafer theory of evidence and its successors, most notably subjective logic, and the third branch originated from game theory. It is, however, important to note that at the core of trust there are Cognition, Assessment processes, and they are governed by various factors. Consequently, trust management methodologies should take these factors, which may ne rational, irrational, contextual, etc., into account. This research contribution will therefore provide an extensive overview of existing methodologies in the computer sciences field, followed by their evaluation in terms of their advantages and disadvantages. Further, some latest experimental results will be given that identify and evaluate some of those most important factors mentioned above. Finally, we will present a new trust management methodology called Qualitative Assessment Dynamics, QAD (aka Qualitative Algebra) that complements existing methodologies mentioned above, and that is aligned with the results of the latest experimental findings.

  • Trust management methodologies for the web
    Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics), 2011
    Co-Authors: D. Trček
    Abstract:

    Trust and its support with appropriate trust management methodologies and technologies is becoming one crucial element for wider acceptance of web services. In the computing society trust and related issues were addressed already in the nineties of the former century, but the approaches from that period were about security, more precisely security services and security mechanisms. These approaches were followed by more advanced ones, where the first branch was based on Bayesian statistics, the second branch was based on Dempster-Shafer theory of evidence and its successors, most notably subjective logic, and the third branch originated from game theory. It is, however, important to note that at the core of trust there are Cognition, Assessment processes, and they are governed by various factors. Consequently, trust management methodologies should take these factors, which may ne rational, irrational, contextual, etc., into account. This research contribution will therefore provide an extensive overview of existing methodologies in the computer sciences field, followed by their evaluation in terms of their advantages and disadvantages. Further, some latest experimental results will be given that identify and evaluate some of those most important factors mentioned above. Finally, we will present a new trust management methodology called Qualitative Assessment Dynamics, QAD (aka Qualitative Algebra) that complements existing methodologies mentioned above, and that is aligned with the results of the latest experimental findings. © 2011 Springer-Verlag Berlin Heidelberg.

Chris Edgar - One of the best experts on this subject based on the ideXlab platform.

  • Cognition Assessment in paediatric clinical trials
    Drug Discovery Today, 2020
    Co-Authors: Chris Edgar, Keith Wesnes
    Abstract:

    As in adults and the elderly, a number of paediatric conditions have a recognised cognitive dysfunction. Studies also demonstrate adverse cognitive effects associated with medicinal products used in paediatric populations. Demonstrating efficacy in treating cognitive dysfunction, or safety and tolerability in minimising adverse cognitive effects is as relevant to paediatric clinical trials as it is to adult populations. Indeed, cognitive Assessments may be even more vital in paediatric populations, due to the additional possibility of adverse effects on cognitive development. This requirement to evaluate Cognition in children and adolescents, and new legislation for paediatric clinical trials, has created an increased demand for suitable Assessment methods.

  • computerized Cognition Assessment during acetylcholinesterase inhibitor treatment in alzheimer s disease
    Acta Neurologica Scandinavica, 2010
    Co-Authors: Keith Wesnes, Chris Edgar, N. Andreasen, Peter Annas, Hans Basun, Lars Lannfelt, Henrik Zetterberg, Kaj Blennow, Lennart Minthon
    Abstract:

    Objectives - Alzheimer's disease Assessment scale-cognitive subscale (ADAS-Cog) has become a standard clinical trials outcome for Cognition, but has been recognized as deficient in areas including coverage of cognitive domains, sensitivity and standardization. Computerized test batteries may address some of these issues. The cognitive drug research computerized Assessment (CDR) system is validated in Alzheimer's disease (AD). This study was designed to further evaluate validity in relation to ADAS-Cog, mini mental state examination (MMSE) and cerebrospinal fluid (CSF) biomarkers and psychometric properties, in a population of Alzheimer's patients on stable anticholinesterase treatment. Materials and methods - Patients completed Cognition Assessments, CSF and blood sampling at baseline and 6 months later. Data for 65 patients were evaluated. Results - The CDR system demonstrated good psychometric properties in this population. Measures of psychomotor speed showed possible sensitivity to decline over 6 months. Conclusions - There are a number of methodological problems with current Cognition Assessment methodology for clinical trials. Computerized measures and in particular millisecond reaction time measures, may address many of these issues.

  • Computerized Cognition Assessment during acetylcholinesterase inhibitor treatment in Alzheimer’s disease
    Acta Neurologica Scandinavica, 2009
    Co-Authors: Keith Wesnes, Chris Edgar, N. Andreasen, Peter Annas, Hans Basun, Lars Lannfelt, Henrik Zetterberg, Kaj Blennow, Lennart Minthon
    Abstract:

    Objectives - Alzheimer's disease Assessment scale-cognitive subscale (ADAS-Cog) has become a standard clinical trials outcome for Cognition, but has been recognized as deficient in areas including coverage of cognitive domains, sensitivity and standardization. Computerized test batteries may address some of these issues. The cognitive drug research computerized Assessment (CDR) system is validated in Alzheimer's disease (AD). This study was designed to further evaluate validity in relation to ADAS-Cog, mini mental state examination (MMSE) and cerebrospinal fluid (CSF) biomarkers and psychometric properties, in a population of Alzheimer's patients on stable anticholinesterase treatment. Materials and methods - Patients completed Cognition Assessments, CSF and blood sampling at baseline and 6 months later. Data for 65 patients were evaluated. Results - The CDR system demonstrated good psychometric properties in this population. Measures of psychomotor speed showed possible sensitivity to decline over 6 months. Conclusions - There are a number of methodological problems with current Cognition Assessment methodology for clinical trials. Computerized measures and in particular millisecond reaction time measures, may address many of these issues.